Regulatory approval

Published by the Health Canada.

Health Canada approved tasigna for the treatment of the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.

This is written in the approval document as:

TASIGNA (nilotinib) 150mg and 200mg capsules are indicated for the treatment of pediatric patients 2 years of age and older with newly diagnosed Ph+ CML-CP.

Citation

Novartis Pharmaceuticals Canada Inc. Tasigna (nilotinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076372.PDF. Revised July 2024. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HC (1) BCR::ABL1 Chronic Myelogenous Leukemia Nilotinib
HC (1) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib